Sino Biopharm Injects 142 Million Yuan into LaNova Medicines

MT Newswires Live11-20

Sino Biopharmaceutical (HKG:1177) invested 142 million yuan in LaNova Medicines' Series C1 financing round, securing a 4.91% stake in the company.

The funding round, which raised 300 million yuan, will support LaNova's development of new medical treatments and innovative platforms in oncology.

The parties also established cooperation in mainland China, focusing on LaNova's LM-108, a drug undergoing clinical trials to treat various cancers.

In addition, Sino Biopharm has the option to enter into other partnerships with LaNova in the future for various potential bispecific antibodies and antibody-drug conjugates.

"Through the equity investment and strategic cooperation, the Group's pipeline layout in the field of oncology will be further enriched and optimized," Sino Biopharm said in a Wednesday statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484419527?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 18:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484419527","market":"fut","top_or_hot":-1,"title":"Sino Biopharm Injects 142 Million Yuan into LaNova Medicines","media":"MT Newswires Live","content":"<html><body><p> Sino Biopharmaceutical (HKG:1177) invested 142 million yuan in LaNova Medicines' Series C1 financing round, securing a 4.91% stake in the company.</p><p>The funding round, which raised 300 million yuan, will support LaNova's development of new medical treatments and innovative platforms in oncology.</p><p>The parties also established cooperation in mainland China, focusing on LaNova's LM-108, a drug undergoing clinical trials to treat various cancers.</p><p>In addition, Sino Biopharm has the option to enter into other partnerships with LaNova in the future for various potential bispecific antibodies and antibody-drug conjugates.</p><p>\"Through the equity investment and strategic cooperation, the Group's pipeline layout in the field of oncology will be further enriched and optimized,\" Sino Biopharm said in a Wednesday statement.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharm Injects 142 Million Yuan into LaNova Medicines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharm Injects 142 Million Yuan into LaNova Medicines\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 18:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sino Biopharmaceutical (HKG:1177) invested 142 million yuan in LaNova Medicines' Series C1 financing round, securing a 4.91% stake in the company.The funding round, which raised 300 million yuan, will...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484419527","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484419527","pubTimestamp":1732099862,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sino Biopharmaceutical  invested 142 million yuan in LaNova Medicines' Series C1 financing round, securing a 4.91% stake in the company.The funding round, which raised 300 million yuan, will support LaNova's development of new medical treatments and innovative platforms in oncology.The parties also established cooperation in mainland China, focusing on LaNova's LM-108, a drug undergoing clinical trials to treat various cancers.In addition, Sino Biopharm has the option to enter into other partnerships with LaNova in the future for various potential bispecific antibodies and antibody-drug conjugates.\"Through the equity investment and strategic cooperation, the Group's pipeline layout in the field of oncology will be further enriched and optimized,\" Sino Biopharm said in a Wednesday statement.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药","BK1589":"北水核心资产","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","MDCO":"麦迪逊医药"},"translate_title":"中国生物制药向LaNova Medicines注资1.42亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1,"01177":0.9},"content_text":"Sino Biopharmaceutical (HKG:1177) invested 142 million yuan in LaNova Medicines' Series C1 financing round, securing a 4.91% stake in the company.The funding round, which raised 300 million yuan, will support LaNova's development of new medical treatments and innovative platforms in oncology.The parties also established cooperation in mainland China, focusing on LaNova's LM-108, a drug undergoing clinical trials to treat various cancers.In addition, Sino Biopharm has the option to enter into other partnerships with LaNova in the future for various potential bispecific antibodies and antibody-drug conjugates.\"Through the equity investment and strategic cooperation, the Group's pipeline layout in the field of oncology will be further enriched and optimized,\" Sino Biopharm said in a Wednesday statement.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484419527"}